Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
COMPOSITION AND METHODS OF INHIBITING AMYLASE-MEDIATED HYDROLYSIS OF ALPHA (1 to 4)-LINKED GLUCOSE POLYMERS
Document Type and Number:
WIPO Patent Application WO/2016/179461
Kind Code:
A3
Abstract:
PAZ320, a mixture of two galactomannans (GMa and GN/ΙΡβ), is being developed to treat diabetes and inflammatory diseases. Both GMα and GMβ have a β(1->4) mannan backbone, with a high density of α( 1->6) linked galactose units. When ingested by diabetic patients, PAZ320 reduces the magnitude of postprandial glucose excursions. PAZ320 functions by binding to enzymes that hydrolyze starch in the gastrointestinal track and thereby reduces steady-state concentrations of low molecular weight sugars like glucose. PAZ320 binds to the α-amylase enzyme from human and porcine sources and thereby attenuates the rate of amylase-mediated hydrolysis of α(1->4)-linked glucose polymers (starch and maltohexaose).

Inventors:
PLATT DAVID (US)
Application Number:
PCT/US2016/031120
Publication Date:
February 16, 2017
Filing Date:
May 06, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
BOSTON THERAPEUTICS INC (US)
International Classes:
A23L29/238; A61P3/10; A61K31/715; A61K31/736; A61K36/48; A61K36/482
Foreign References:
US20130302471A12013-11-14
Other References:
TRASK ET AL.: "Treatment With Novel Glactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin", JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, vol. 8, no. 5, 2014, pages 1018 - 1022, XP055364457
"Boston Therapeutics Initiates Research Study on PAZ320 at University of Minnesota", BOSTON THERAPEUTICS, 15 October 2013 (2013-10-15), XP055364460, Retrieved from the Internet [retrieved on 20161205]
Attorney, Agent or Firm:
SERIO, John, C. et al. (US)
Download PDF: